Takamizawa Shigeatsu, Kojima Junya, Umezu Tomohiro, Kuroda Masahiko, Hayashi Shigehiro, Maruta Takenori, Okamoto Aikou, Nishi Hirotaka
Department of Obstetrics and Gynecology, Tokyo Medical University, Tokyo 160-0023, Japan.
Department of Molecular Pathology, Tokyo Medical University, Tokyo 160-8402, Japan.
Mol Clin Oncol. 2023 Dec 28;20(2):14. doi: 10.3892/mco.2023.2712. eCollection 2024 Feb.
Ovarian cancer is a malignant gynecologic disease rarely diagnosed in the early stages. Among the various types of ovarian cancer, clear cell carcinoma has a poor prognosis due to its malignant potential. MicroRNAs (miRNAs/miRs) regulate gene expression in cells by suppressing the translation of target genes or by degrading the target mRNA. miRNAs are also secreted from the cells in the blood, binding to proteins or lipids and assisting in cell-cell communication. Therefore, serum miRNAs may be considered potential diagnostic biomarkers for ovarian cancer. The present study investigated and identified specific miRNAs associated with ovarian clear cell carcinoma and compared them to those in ovarian endometrioma samples and healthy controls. CA125, an ovarian tumor marker, did not differ between patients with ovarian clear cell carcinoma, endometriosis or healthy controls. Subsequently, four miRNAs (miR-146a-5p, miR-191-5p, miR-484 and miR-574-3p) were analyzed. The expression levels of miR-146a-5p and miR-191-5p were significantly increased in the serum samples from patients with ovarian clear cell carcinoma compared with those in the healthy controls, but there was no significant difference compared with in patients with endometriosis. Furthermore, the bioinformatics analysis showed that and were the candidate target genes of miR-146a-5p and miR-191-5p. In conclusion, the results of the present study demonstrated that miR-146a-5p and miR-191-5p may be useful as early and non-invasive diagnostic tools in ovarian clear cell carcinoma. These miRNAs can help in distinguishing between ovarian clear cell carcinoma and ovarian endometrioma. To the best of our knowledge, no previous studies have screened any candidates specifically for ovarian clear cell carcinoma.
卵巢癌是一种很少在早期被诊断出来的恶性妇科疾病。在各种类型的卵巢癌中,透明细胞癌因其恶性潜能而预后较差。微小RNA(miRNA/miR)通过抑制靶基因的翻译或降解靶mRNA来调节细胞中的基因表达。miRNA也从血液中的细胞分泌出来,与蛋白质或脂质结合并协助细胞间通讯。因此,血清miRNA可能被认为是卵巢癌潜在的诊断生物标志物。本研究调查并鉴定了与卵巢透明细胞癌相关的特定miRNA,并将它们与卵巢子宫内膜异位囊肿样本和健康对照中的miRNA进行了比较。卵巢肿瘤标志物CA125在卵巢透明细胞癌患者、子宫内膜异位症患者或健康对照之间没有差异。随后,分析了四种miRNA(miR-146a-5p、miR-191-5p、miR-484和miR-574-3p)。与健康对照相比,卵巢透明细胞癌患者血清样本中miR-146a-5p和miR-191-5p的表达水平显著升高,但与子宫内膜异位症患者相比没有显著差异。此外,生物信息学分析表明, 和 是miR-146a-5p和miR-191-5p的候选靶基因。总之,本研究结果表明,miR-146a-5p和miR-191-5p可能作为卵巢透明细胞癌早期和非侵入性诊断工具。这些miRNA有助于区分卵巢透明细胞癌和卵巢子宫内膜异位囊肿。据我们所知,以前没有研究专门筛选过卵巢透明细胞癌的任何候选物。